Dynavax Technologies (NASDAQ:DVAX) Hits New 52-Week High – Here’s What Happened

Dynavax Technologies Co. (NASDAQ:DVAX) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $14.07 and last traded at $14.08, with a volume of 78480 shares traded. The stock had previously closed at $13.88.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. The Goldman Sachs Group lowered shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their price target for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, HC Wainwright restated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Trading Down 0.3 %

The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The stock has a market capitalization of $1.72 billion, a P/E ratio of 76.94 and a beta of 1.32. The stock has a 50-day moving average price of $12.93 and a two-hundred day moving average price of $12.16.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million for the quarter, compared to analysts’ expectations of $72.70 million. On average, research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Dynavax Technologies

Several hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE boosted its position in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 1,169 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Dynavax Technologies in the fourth quarter worth $35,000. Finally, Capital Performance Advisors LLP bought a new position in Dynavax Technologies in the third quarter worth $45,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.